Hepatocellular carcinoma prognosis depends on both liver and tumor determinants, especially on maximum tumor diameter, multifocality, and presence of portal vein thrombosis, despite apparently complete tumor removal by resection or liver transplantation.
-
2021 (v1)PublicationUploaded on: April 14, 2023
-
2022 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2021 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2023 (v1)Publication
Background and Aims: Hepatocellular carcinoma (HCC) recurrence is common in patients treated with liver resection (LR). In this study, we aimed to evaluate the incidence and preoperative predictors of non-transplantable recurrence in patients with single HCC <= 5 cm treated with frontline LR.Methods: From the Italian Liver Cancer (ITA. LI.CA)...
Uploaded on: July 3, 2024 -
2021 (v1)Publication
Epidemiology of hepatocellular carcinoma (HCC) is changing in most areas of the world. This study aimed at updating the changing scenario of etiology, clinical presentation, management and prognosis of HCC in Italy during the last 15 years.
Uploaded on: March 27, 2023 -
2022 (v1)Publication
No description
Uploaded on: February 11, 2024 -
2021 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2021 (v1)Publication
Sorafenib is the gold standard therapy for the advanced hepatocellular carcinoma (HCC). No scoring/staging is universally accepted to predict the survival of these patients.
Uploaded on: April 14, 2023 -
2023 (v1)Publication
Background & aims: Alcohol abuse and metabolic disorders are leading causes of hepatocellular carcinoma (HCC) worldwide. Alcohol-related aetiology is associated with a worse prognosis compared with viral agents, because of the lower percentage of patients diagnosed with HCC under routine surveillance and a higher burden of comorbidity in...
Uploaded on: February 13, 2024